The global vaccine industry has hit pay dirt, thanks to the COVID-19 pandemic! Never has it been so good for the industry.
The scramble to find medical solutions to one of the worst nightmares that haunts humanity has found a forceful response from the vaccine industry. We now have vaccines which promise protection against this horrible pandemic. The world is now more positive about the post pandemic future albeit with new social norms.
Once perceived to be cheap with production in the ambit of government institutes, and largely ignored by the pharmaceutical majors, vaccines are now perceived to be of immense social value and new business growth drivers in the pharmaceutical industry.
The defining changes came about at the beginning of this century with the United Nations adopting the Millennium Development Goal (MDG) in 2000 of reducing child mortality by half by 2015. Impetus to this was given by the creation of Global Alliance for Vaccines and Immunization (GAVI) in 2000 to fund immunization initiatives in low-income countries, and more importantly develop low-cost vaccine solutions alongside new vaccine technologies. This apart, new recombinant biotechnology methods were able to address vaccine solutions to pressing infectious disease needs.
The private sector seized the initiatives and blockbuster vaccines soon hit the market. For example, the pneumococcal vaccine market is now worth $8 billion, the human papilloma virus (HPV) vaccine is worth $3.8 billion, and the rotavirus vaccine is worth $1.6 billion. No longer are vaccines in the ambit of government institutes. No longer are they perceived as cheap. No longer are they low in the priority list of pharmaceutical majors.
هذه القصة مأخوذة من طبعة February 2021 من Bio Spectrum.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك ? تسجيل الدخول
هذه القصة مأخوذة من طبعة February 2021 من Bio Spectrum.
ابدأ النسخة التجريبية المجانية من Magzter GOLD لمدة 7 أيام للوصول إلى آلاف القصص المتميزة المنسقة وأكثر من 9,000 مجلة وصحيفة.
بالفعل مشترك? تسجيل الدخول
Economic Survey Lays Focus On Mental Healthcare For The First Time
For the first time ever, the Economic Survey 2023-24 tabled by the Union Minister of Finance and Corporate Affairs Nirmala Sitharaman in Parliament recently, talks extensively about mental health, its significance and implications on policy recommendations.
IIT-G discovers RNA-destroying function of p30 protein in African Swine Fever Virus
Indian Institute of Technology Guwahati (IIT-G) researchers have investigated the biochemistry of the African Swine Fever Virus (ASFV) protein, focusing on understanding the biochemical processes of infection to devise effective control strategies.
13th Bengaluru INDIA NANO 2024 brings together 1018 delegates, 3,000+ visitors
The 13th edition of Bengaluru INDIA NANO 2024, organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS), and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) concluded on August 3 with participation of 1018 delegates, 11 countries including Korea, Morocco, USA, UK, France, Canada, Germany, Netherlands, Russia, Japan, and Poland, 49 exhibitors comprising 21 startups and 28 industry and institutes, and 200 posters. The exhibition had a footfall of 3,000+ visitors.
Are Nutraceuticals DRUGS? Examining a Needless Regulatory Tussle
The news has been around for a while which has put a big question mark ahead of the Indian nutraceuticals industry.
Can India Reclaim API Throne from China?
Despite having the third-largest pharmaceutical industry by volume in the world and being the largest manufacturer of generic medicines globally, India is heavily dependent on China for imports of raw materials, Key Starting Materials (KSMs), and Active Pharmaceutical Ingredients (APIs).
JRS Pharma & Gujarat Microwax open new manufacturing facility in Mehsana
JRS Pharma, a leading manufacturer of excipients, in partnership with Gujarat Microwax, has commissioned a new manufacturing facility for cotton-based croscarmellose sodium.
NovaLead's patented repurposed drug for treating DFU gets CDSCO approval
Pune-based NovaLead Pharma has announced that the drug regulator in India, Central Drugs Standard Control Organisation (CDSCO), has approved their patented Repurposed Drug for treatment of Diabetic Foot Ulcer (DFU) which is a global unmet medical need.
Medicamen Organics expands footprint in East Africa with $75,000 investment in Rwanda
Delhi-based pharma company Medicamen Organics has taken a significant step in its global expansion strategy by signing a Memorandum of Understanding (MoU) with Depot Pharmacy Yego in Rwanda.
Mankind Pharma acquires 100% stake in Bharat Serums and Vaccines for Rs 13,630 Cr
Mankind Pharma has entered into a definitive agreement to acquire a 100 per cent stake in Bharat Serums and Vaccines Limited (BSV) from Advent International, for an enterprise value of approx.
Thyrocare buys Polo Labs' pathology diagnostic biz to strengthen Northern India presence
Mumbai-based Thyrocare, a leading diagnostic and preventive healthcare service provider in India, has entered into a Business Transfer Agreement with Polo Labs to acquire their pathology diagnostic business.